<DOC>
	<DOC>NCT02518698</DOC>
	<brief_summary>The goal of the study is to provide a detailed description of treatments for CRPC (Castrate Resistant Prostate Cancer) patients with bone metastases and the resource utilization and costs associated with that diagnosis and subsequent treatments.</brief_summary>
	<brief_title>Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>First diagnosis for bone metastases for members diagnosed with prostate cancer found in the claims data during the identification period Members age ≥ 65 years at index Medicare members with medical and pharmacy coverage; and Continuously enrolled during the pre and postindex periods. Member with diagnosis of any other cancer (excluding melanoma (ICD9 172.x) and other metastases (ICD9 198.x)) before the index date; and Members age ≥ 89 years of age at index date</criteria>
	<gender>Male</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>88 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Castrated resistant prostate cancer</keyword>
	<keyword>Patients with bone metastases</keyword>
</DOC>